Skip to main content

Breogan Rodriguez Acevedo

Institutions of which they are part

Senior researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Breogan Rodriguez Acevedo

Institutions of which they are part

Senior researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Estudio PROBiMS - Efecto de la administración de un probiótico como tratamiento complementario en la esclerósis múltiple: un ensayo clinico aleatorizado, doble ciego y controlado con placebo

IP: Carmen Espejo Ruiz
Collaborators: Carlos Nos Llopis, Herena Eixarch Ahufinger, Mireia Resina Salles, Breogan Rodriguez Acevedo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 227500
Reference: PI24/01122
Duration: 01/01/2025 - 31/12/2027

SGR-Cat 2021: Neuroimmunologia Clínica

IP: SGR-Cat 2021: Neuroimmunologia Clínica
Collaborators: Carlos Nos Llopis, SGR-Cat 2021: Neuroimmunologia Clínica, José Ant. Graells Salvador, Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Manuel Comabella Lopez, Andrea Serrano Mascarós, Margarida Capell Maymo, Samuel Sánchez Pous, Elisenda Anglada Clofent, Montserrat Aroca Alsina, Sergio Cabello, Carmen Tur Gomez, Gabriel Ig Camiña Rodríguez, Herena Eixarch Ahufinger, Carme Santoyo Medina, Oriol Nualart Mundo, Mar Tintore Subirana, M Jesus Arevalo Navines, Edwin Roger Meza Murillo, Augusto Cesar Sao Aviles, Miguel Angel Robles Sanchez, Dunia Muñoz Valdivielso, Carmen Espejo Ruiz, Gaizka Loyola Sanmillan, Mireia Resina Salles, Angela Vidal Jordana, Lucía Gutiérrez Ruiz, Ana Zabalza de Torres, Sergio Vergara Ruiz, Rafael Garcia Merida, Luciana Midaglia Fernandez, Alvaro Cobo Calvo, Neus Mongay Ochoa, Joaquin Castillo Justribo, Milagros Fraga Pereira, Breogan Rodriguez Acevedo, Andres Miguez Gonzalez, Mireia Castillo Juarez, Rucsanda Pinteac, Nicolás Miguel Fissolo
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00782
Duration: 01/01/2022 - 30/06/2025

Rejuvenation of the immune system as a therapeutic approach for progressive multiple sclerosis.

IP: Carmen Espejo Ruiz
Collaborators: Rosalia Horno Ocaña, Herena Eixarch Ahufinger, Breogan Rodriguez Acevedo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI21/01682
Duration: 01/01/2022 - 30/06/2026

Deciphering clinical features and pathogenesis of myelin oligodendrocyte glycoprotein (MOG) antibodies in adult patients with a first demyelinating syndrome

IP: Alvaro Cobo Calvo
Collaborators: Rosalia Horno Ocaña, Cristina Auger Acosta, Luciana Midaglia Fernandez, Breogan Rodriguez Acevedo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 134915
Reference: PI20/00800
Duration: 01/01/2021 - 30/06/2025

Related news

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Related professionals

Pau  Rello Sabaté

Pau Rello Sabaté

Predoctoral researcher
Cardiovascular Diseases
Read more
Mª Teresa Tórtola Fernández

Mª Teresa Tórtola Fernández

Senior researcher
Microbiology
Read more
Montse Bosch Ferrer

Montse Bosch Ferrer

Senior researcher
Clinical Pharmacology
Read more
Ester Mateos Mullor

Ester Mateos Mullor

Gestió i Administració
Quality, Processes and Document Management Unit
Digital Transformation Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.